To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

NCT04618640 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

249

Enrollment

INDUSTRY

Sponsor class

Conditions

Diphtheria
Tetanus
Pertussis
Poliomyelitis

Interventions

BIOLOGICAL: DTaP-IPV combination vaccine

Sponsor

Boryung Biopharma Co., Ltd.